Stocktoria
Sarepta Therapeutics, Inc. SRPT
Sarepta Therapeutics, Inc. (SRPT) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $2.2B at a -32.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.431 |
| Retained earnings / assets | -1.456 |
| EBIT / assets | -0.209 |
| Equity / liabilities | 0.516 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | 4/9 | -2.78 | — | +15.6% |
| PTCT | PTC THERAPEUTICS, INC. | 5/9 | 1.56 | 10.3 | +114.5% |
| ALKS | Alkermes plc. | 5/9 | 6.24 | 38 | -5.2% |
| AMRX | Amneal Pharmaceuticals, Inc. | 7/9 | 2.06 | 76.3 | +8% |
| PAHC | PHIBRO ANIMAL HEALTH CORP | 5/9 | 3.97 | 26.6 | +27.4% |
| INDV | Indivior Pharmaceuticals, Inc. | 4/9 | -0.7 | 24.3 | +4.3% |
| NSRX | Nasus Pharma Ltd | 3/9 | -13.82 | — | — |
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
FAQ
Is SRPT financially healthy?
Sarepta Therapeutics, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SRPT pay a dividend?
No, Sarepta Therapeutics, Inc. does not currently pay a dividend.
How profitable is SRPT?
In FY2025, Sarepta Therapeutics, Inc. had a net margin of -32.5% and a return on equity of -62.5%.
What is the analyst price target for SRPT?
The average Wall-Street price target for Sarepta Therapeutics, Inc. is $22.00, about 19.7% above the recent price, from 23 analysts (consensus: hold).
Is SRPT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Sarepta Therapeutics, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.